Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Amitiza Claims Tripple Gold in August HP Rep Promotion Rankings: Intage
October 4, 2024
- PeptiDream, Curium Join Hands on Radionuclide Therapy for Prostate Cancer
October 3, 2024
- Orion to Take Over Divigel as Its 1st Product in Japan
October 3, 2024
- Ex-BMS Exec Sugita Tapped as President of Nxera Pharma Japan
October 2, 2024
- Shionogi Sole Distributor of Nxera’s Insomnia Med in Japan
October 2, 2024
- Meiji Rolls Out COVID Jab Kostaive in Japan
October 2, 2024
- Enhertu Gets Priority Review for HER2 Low or Ultralow Breast Cancer in US
October 2, 2024
- Pfizer Japan to Suspend Lower-Strength Version of Syphilis Drug
October 1, 2024
- Healios Again Delays Definitive MultiStem Deal with Nobelpharma
October 1, 2024
- Towa, SymBio/Eagle Settle Treakisym Patent Suit
October 1, 2024
- Nippon Kayaku Files Humira Biosimilar for nr-axSpA
October 1, 2024
- Astellas Touts Confirmed Safety and Antitumor Effects of Protein Degrader
September 30, 2024
- Sawai Ordered to Pay 3 Billion Yen in Damages in Teribone Suit, Set to Appeal
September 30, 2024
- 8 South Korean Biotechs Now Housed at Shonan iPark
September 30, 2024
- Shionogi Files Sage’s Depression Drug in Japan
September 30, 2024
- Asahi Kasei to Divest Diagnostics Biz to Nagase in July 2025
September 27, 2024
- Fujirebio Files Blood-Based Diagnostic Test for Alzheimer’s in US
September 27, 2024
- Remitch OD Tablets Earns Indonesia Approval: Toray/Meiji Pharma
September 27, 2024
- RaQualia’s Acid Reducer Tegoprazan Approved in Malaysia
September 27, 2024
- Sawai Joins List of Atomoxetine Recalls after Establishing Test Model
September 27, 2024
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…